Data Explorer

Research historical outbreak investigations and the full recall archive, with charts, trends, and advanced filters. Looking for what's happening right now instead? See current Health Alerts.

Recall totals

All FDA and USDA recalls in Public Health Trace, June 2012 to October 2026.

37,211

Total recall recordsAll FDA and USDA recalls in Public Health Trace

9,841

Class I recallsReasonable probability of serious health consequences

24,366

Class II recallsTemporary or medically reversible health consequences

2,892

Class III recallsNot likely to cause adverse health consequences

Quick insights

A snapshot of the most notable patterns across all recorded FDA and USDA recalls.

Most recalled product100 vegetarian Fenugreek Capsules 90 count, 600mg, packaged in 150cc Amber Glass Packer with White Polypropylene Cap. 53 recalls

Most common hazardLack of Assurance of Sterility 2,073 recalls

Newest recallhttp://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/frutas-y-hortalizas-del-sur-sa-expands-recalls-include-additional-lots-great-value-frozen-organicPublished October 2, 2026

Most affected stateHawaii 200 recalls mention this state

State: ND ×
Clear all

Download matching recalls as CSV

CSV exports include up to 5,000 matching rows (applying your current filters), not the full dataset if it's larger.

Filters

Timeline Classification Table

Metric

Time range

Group by

View

Recalls announced by month (Year to date)

Download CSV

Source: FDA and USDA public dataLast updated October 4, 2026 ET

Summary (Year to date)

1,714 recalls have been announced year to date.
Sep 2026 was 3% higher than the previous complete period (Aug 2026: 182).
The highest complete period was Jun 2026 (297).
Oct 2026 is incomplete and not included in the figures above.

Complete data
Incomplete

Recalls by class

Recalls by class
Class	Recalls
Class II	24,366
Class I	9,841
Class III	2,892
Not Yet Classified	2

Download CSV

Recalls by class
Class	Recalls
Class II	24,366
Class I	9,841
Class III	2,892
Not Yet Classified	2

FDA Recall Terminated Historical recordClass II

Omnipaque 240mg/mL PF, 300mg/mL PF, in 3 mL, 5 mL, and 10 mL, vials, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Lack of Assurance of Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Lidocaine 1% PF, 2% PF, and 4% PF, in 1 mL, 2 mL, 5 mL, and 10 mL vials, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Lack of Assurance of Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Lidocaine/Dextrose 5%/7.5% PF, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Lack of Assurance of Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Isovue 200 mg/mL PF and 300 mg/mL PF, Vials, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Lack of Assurance of Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Hyaluronidase 150 u/ml PF, 1 mL, 5 mL, and 10 mL vials, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Lack of Assurance of Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Glycerin 100% PF, 1mL, 2 mL, and 5 mL vials, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Lack of Assurance of Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Dexamethasone Sodium Phosphate 4 mg/mL vials PF, 6 mg/mL PF vials, and 8 mg/mL PF vials, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Lack of Assurance of Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Clonidine 100 mcg/mL PF, 1mL and 2 mL vials, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Lack of Assurance of Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Bupivacaine 0.25% PF, Bupivacaine 0.5% PF, and Bupivacaine 0.75% PF, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Lack of Assurance of Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Betamethasone Sodium Phosphate 6 mg/mL P Injection, Betamethasone Sodium Phosphate 6 mg/mL PF Injection, Betamethasone Sodium Phosphate 8 mg/mL PF Injection, Betamethasone Sodium Phosphate 12 mg/mL PF Injection, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Lack of Assurance of Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Betamethasone Repository 6 mg/mL PF Injection and Betamethasone Repository 6 mg/mL P Injection, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Lack of Assurance of Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass I

Methylprednisolone Acetate 80 mg/mL Injection, Preserved, supplied in 5 mL and 10 mL vials, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Non-Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass I

Methylprednisolone Acetate 40 mg/mL Injection, Preserved, supplied in 5 mL and 10 mL vials, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Non-Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass I

Methylprednisolone Acetate (PF) 40 mg/ml Injection, supplied in 1 mL, 2 mL and 5 mL vials, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Non-Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass I

Methylprednisolone Acetate (PF) 80 mg/ml Injection, supplied in 1 mL, 2 mL and 5 mL vials, manufactured by New England Compounding Center, Framingham, MA

by New England Compounding Center

Reason: Non-Sterility
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Synthroid (Levothyroxine Sodium) tablets, 150 mcg (0.15 mg), 90 tablets per bottle, Rx Only, NDC 0074-7069-90; ABBOTT LABORATORIES NORTH CHICAGO, IL 60064 U.S.A.

by Abbott Laboratories

Reason: Labeling: Error on Declared Strength. Product labeled to contain 150 mcg tablets actually contained 75 mcg tablets.
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Epinephrine Injection USP, 1 mL, USP 1:1000 (1 mg/mL), SQ/IM, Hospira, Inc., Lake Forest, IL --- NDC 0409-7241-01

by Hospira Inc.

Reason: Presence of Particulates; may contain glass particles
Published: January 9, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Levothyroxine Sodium Tablets, USP, 175 mcg in 90 ct bottles, Manufactured by Patheon Puerto Rico Inc., for Alara Pharmaceutical Corp, San Juan, PR

by Alara Pharmaceutical Co

Reason: Subpotent; 15 month stability
Published: January 2, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Levothroid (levothyroxine sodium tablets, USP), 75 mcg., 100-count bottles, Rx only, NDC 0456-1322-01, Manufactured for Forest Pharmaceuticals, Inc., Subsidiary of Forest Laboratories, Inc., St. Louis, MO, by Lloyd Pharmaceutical, Shenandoah, IA.

by Lloyd Inc. of Iowa

Reason: Subpotent; 9-month stability interval
Published: January 2, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Thyro-Tab 0.075 mg., packaged in 150,000-tablet bulk drums for repackaging, RX. The firm name on the label is Lloyd Pharmaceutical, Shenandoah, IA

by Lloyd Inc. of Iowa

Reason: Subpotent; 9-month stability interval
Published: January 2, 2013
Distribution: Nationwide

View recall →

Data last updated: October 4, 2026 ET

Recall records are summarized from official FDA and USDA sources. Notices may be updated, reclassified, terminated, or withdrawn. Always review the linked official notice for the most current instructions. Read the full medical disclaimer.